🇺🇸 FDA
Patent

US 8795964

GRM3 mutations and use thereof for the diagnosis and treatment of melanoma

granted A61KA61K31/4184

Quick answer

US patent 8795964 (GRM3 mutations and use thereof for the diagnosis and treatment of melanoma) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Jul 31 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Aug 05 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 31 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/4184